Medifast Q2 revenue falls 37%

Overview

• Medifast Q2 2025 revenue falls 37% yr/yr but beats analyst expectations, per LSEG data

• Net income for Q2 2025 at $2.5 mln, aided by LifeMD stock gain

• Co focuses on coach growth and productivity initiatives amid revenue decline

Outlook

• Medifast expects Q3 2025 revenue between $70 mln and $90 mln

• Company anticipates Q3 2025 diluted EPS between ($0.60) and $0.00

Result Drivers

• COACH DECLINE - Revenue fell due to a 32.7% decrease in active earning OPTAVIA coaches, driven by client acquisition challenges

• CLIENT ACQUISITION - Continued pressure on client acquisition affected average revenue per coach, reflecting broader market challenges

• GLP-1 IMPACT - Rapid adoption of GLP-1 medications for weight loss contributed to revenue decline

Key Details

Analyst Coverage

• The one available analyst rating on the shares is "hold"

• The average consensus recommendation for the food processing peer group is "buy."

• Wall Street's median 12-month price target for Medifast Inc is $15.00, about 8.3% above its August 1 closing price of $13.75

Press Release: ID:nBw75hr03a